logging in or signing up P-Glycoproteins drmayur2511 Download Post to : URL : Related Presentations : Let's Connect Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Copy embed code: Embed: Flash iPad Dynamic Copy Does not support media & animations Automatically changes to Flash or non-Flash embed WordPress Embed Customize Embed URL: Copy Thumbnail: Copy The presentation is successfully added In Your Favorites. Views: 1523 Category: Education License: All Rights Reserved Like it (0) Dislike it (0) Added: July 18, 2011 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript P-Glycoproteins: P-Glycoproteins Dr. Mayur M. Maybhate JR II, Dept. of Pharmacology IGGMC, Nagpur.Slide 2: Introduction Structure Location and functions Substrates and inhibitors Important interactions Future trends ConclusionIntroduction: Introduction Transporters are membrane proteins Control the influx of essential nutrients and ions and the efflux of cellular waste, toxins and drugs Controls cellular homeostasisSlide 4: Transporters in body ATP binding cassette Solute carrier (ABC) (SLC) ABC-B (1-11) SLC (1-43) ABC-C (1-13) ABC-A (1-12) ABC-B1 (P-glycoprotein)Transporters and drug responses: Transporters and drug responses Pharmacokinetic – Absorption, metabolism, excretion of drugsSlide 6: Pharmacodynamics – Target for many drugs e.g. SSRIs, TCAsMechanism of membrane transport: Mechanism of membrane transportP-Glycoprotein: P-Glycoprotein Most important member of ABC family Transmembrane protein coded by MDR-1 gene Functions to actively pump a diverse array of xenobiotics out of the cells in which it is expressedHistorical aspects: Historical aspects First described in 1976, by JULIANO & LING in Chinese hamster ovary cells selected in culture for colchicines resistance PULLIAM et al. in 1985 discovered the particular increased penetration of ivermectin through the BBB resulting in 31-fold higher concentration of the drug in the brain than in the plasma in MDR knocked out miceSlide 10: MICKISCH et al., 1991, found P-glycoprotein inhibition due to cyclosporine enhanced paclitaxel (Taxol) oral bioavailabilityStructure: Structure Single polypeptide Two homologous halves Each contains six transmembrane domains and a hydrophilic region with an ATP-binding domainLocations and function: Locations and function 1) Epithelial cells of gastrointestinal tract Influx of essential nutrients and ions and efflux of cellular waste , drugs etc. Extensive overlap in the substrate specificities and tissue localization of P- gp and drug metabolizing enzyme in the cytochrome P450 (CYP3A4)Slide 13: Lead to the hypothesis that these two proteins work together to protect the body from absorption of harmful xenobiotics, acting synergistically in the small intestineSlide 15: 2) Hepatocytes in liver Even if drug is absorbed it is expelled into bile, enters intestine again Work synergistically with CYP3A4 in liverSlide 16: 3) Renal epithelial cells Efflux of drugs into tubular lumen, easily excretedSlide 17: 4) Tissues with barrier function Blood brain Blood testis Blood placenta limiting entry and accumulation of many drugs into the brain and contributing to the protective function of the central nervous systemSlide 18: 5) Cancer cells Highly expressed, leading to efflux of anticancer agents from cells Resistance to these agentsSubstrates and inhibitors: Substrates and inhibitors Various classes of drugs Resulting in efflux of drug from body, lowering their plasma concentrationImportant interactions: Important interactions P- gp induction or inhibition may have a substantial effect on the pharmacokinetics and pharmacodynamics of concomitantly administered drugs that are substrates for this transporter.Slide 22: Digoxin Absorption reduced due to co-administration of rifampicin (MDR1 inducer) Renal excretion retarded due to concurrent administration of MDR1 inhibitors (verapamil, quinidine etc.)Slide 23: Loperamide Peripheral opioid for diarrhea, substrate for P-glycoprotein Co-administration of quinidine has caused marked respiratory depressionSlide 24: Protease inhibitors Ritonavir , Nelfinavir , Indinavir , Saquinavir substrates for P-glycoprotein P- gp transport at the intestinal and/or hepatic level limits the systemic bioavailability Poor penetration into the brain, testis Treatment ineffective and development of resistance fasterSlide 25: Anticancer agents MDR1 highly expressed in cancer cells, rendering resistant to anticancer agents Reduced bioavailability Paclitaxel, actinomycin D, vincristine etc. substrates for P- gp .Future trends: Future trends P- gp induction does not have a therapeutic role till date , P- gp inhibition is an attractive therapeutic approach to reverse multidrug resistanceAnticancer therapy: Anticancer therapy Strategies to modulate P- gp function are being pursued actively in oncology reversal of multidrug resistance in tumours several newly developed agents that inhibit P- gp function are in phase I-III clinical trials. e.g. ONT 093 PSC 31665Antiretroviral therapy: Antiretroviral therapy Blockage of P- gp may be useful in facilitating greater intestinal absorption, bioavailability and penetration of protease inhibitors into HIV sanctuary sites as well as reduced excretion. Simplify protease inhibitor-containing regimens by reducing the oral doses of protease inhibitors and the frequency at which they are takenLinks with diseases: Links with diseases MDR1 gene polymorphisms increases susceptibility to diseases such as Parkinson's disease, inflammatory bowel disease, multi-drug resistant epilepsy and renal carcinoma. MDR1 induction beneficial ???Conclusion: Conclusion P-glycoprotein encoded by MDR1 gene that influences drug pharmacokinetic and Pharmacodynamics P- gp inhibition is an attractive therapeutic approach to reverse multidrug resistanceReferences: References Kathleen M. Giacomini and Yuichi Sugiyama membrane transporters and drug response ; Goodman and Gilman's , Pharmacological basis of therapeutics;11;40-65;2005. Bertram G. Katzung , Introduction, Basic and clinical pharmacology:11:9-10;2009Slide 33: BRADY, J.M. et al., Tissue distribution and chemical induction of multiple drug resistance genes in rats; Drug Metabolism and Disposition , Baltimore; vol.30; 7; 2005. CUMMINS, C. L. et al. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model; Journal of Pharmacology and Experimental Therapeutics , Baltimore; v.305, n.1; p.306-314; 2006.Slide 34: FROMM, M.F. Importance of P-glycoprotein at blood-tissue barriers; TRENDS in Pharmacological Sciences ; v.25; n.8; p.423-429; 2004. KHARASCH, E.D. et al. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. British Journal of Clinical Pharmacology , Oxford, v.57; n.5; p.600-610, 2003.Slide 35: THANK YOU You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.